CTX-110 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in B-Cell Chronic Lymphocytic Leukemia. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of CTX-110’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CTX-110 is expected to reach an annual total of $105 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CTX-110 Overview
CTX-110 (previously known as CTX-101) is under development for the treatment of B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), Richter’s transformation of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. The drug candidate comprises of genetically modified chimeric antigen receptor (CAR-T) cells that acts by targeting tumor cells expressing B lymphocyte antigen CD19. It is administered through intravenous route and is being developed based on CRISPR’s gene-editing technology.
CRISPR Therapeutics Overview
CRISPR Therapeutics is a gene editing company. The company’s portfolio consists of multiple therapeutic programs, including its proprietary technology, CRISPR (Clustered, Regularly Interspaced Short Palindromic Repeats)/Cas9 (CRISPR-associated protein-9), to precisely alter specific sequences of genomic deoxyribonucleic acid (DNA). The company’s products are primarily used in the healthcare industry, specifically in the treatment and prevention of both rare and common diseases. Its portfolio includes multiple therapeutic programs in areas such as hemoglobinopathies, immuno-oncology, autoimmune diseases, and type 1 diabetes. The company’s advanced program, Casgevy, is approved for treating severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CRISPR Therapeutics is headquartered in Zug, Switzerland.
The company reported revenues of (US Dollars) US$371.2 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$1.2 million in FY2022. The operating loss of the company was US$222.5 million in FY2023, compared to an operating loss of US$673.2 million in FY2022. The net loss of the company was US$153.6 million in FY2023, compared to a net loss of US$650.2 million in FY2022.
The company reported revenues of US$0.5 million for the second quarter ended June 2024, an increase of 2.6% over the previous quarter.
For a complete picture of CTX-110’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.